 CAMBRIDGE, Mass., June 29, 2021 GLOBE NEWSWIRE -- Vericel Corporation NASDAQ:VCEL, a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its development partner, MediWound Ltd., received a complete response letter CRL from the U.S. Food and Drug Administration FDA regarding the Biologics License Application BLA for NexoBrid, a potential treatment for eschar removal in adults with deep partial-thickness andor full-thickness burns. 